Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,192,775
-
Share change
-
+17,645
-
Total reported value
-
$1,298,025
-
Put/Call ratio
-
16%
-
Price per share
-
$1.09
-
Number of holders
-
28
-
Value change
-
+$26,651
-
Number of buys
-
10
-
Number of sells
-
10
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2022
As of 30 Jun 2022,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,192,775 shares.
The largest 10 holders included
MEITAV DASH INVESTMENTS LTD, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Spire Wealth Management, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., JANE STREET GROUP, LLC, TWO SIGMA ADVISERS, LP, CITADEL ADVISORS LLC, Virtu Financial LLC, and CAPITAL PERFORMANCE ADVISORS LLP.
This page lists
27
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.